HLS Therapeutics Inc.
TSX:HLS.TODrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $116.32M
- Beta
- 0.85
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.33
Volume 0.04M
Average 0.01M
HLS.TO Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
HLS Therapeutics Inc.TSX: HLS.TO
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $12.65M rose 0.2% year over year, ahead of the -1.8% change in trailing-twelve-month revenue. Sequentially, it fell 18.0% from the prior quarter. Over 3 fiscal years it compounded at -2.8% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $58.13M (+2.9%) for the fiscal year ending Dec 2026, a step up from the -0.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $12.65M-18.0% QoQ
- Last fiscal yearDec 2025
- $56.47M-0.3% YoY
- LTMMar 2026
- $55.76M-1.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +0.2% | -0.2% | -0.4 pp |
| 1 year | -0.3% | +2.9% | +3.2 pp |
| 3-year CAGR | -2.8% | +11.7% | +14.5 pp |
| 5-year CAGR | +11.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 56.47M USD
- Year-over-year change
- -0.3%
- 4-year CAGR
- -1.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 56.47M | -0.3% |
| FY2024 | 2024-12-31 | 56.62M | -10.2% |
| FY2023 | 2023-12-31 | 63.07M | +2.6% |
| FY2022 | 2022-12-31 | 61.47M | +2.4% |
| FY2021 | 2021-12-31 | 60.01M | — |
Revenue vs competitors
How HLS.TO compares with its peers on the latest reported figures
- HLS.TO's LTM Mar 2026 revenue of $55.76M is the 4th highest of the 7 companies compared; the peer median is $68.6M.
- Its year-over-year change of -1.8% is the 5th highest of 6, against a peer median of +9.3%.
- Over three fiscal years its annual growth of -2.8% compares with a peer median of +8.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $10.85B | +10.1% | +8.1% | |
| LTM Jun 2026 | $3.12B | +9.3% | +10.9% | |
| LTM Mar 2026 | $86.93M | +79.9% | +55.5% | |
| LTM Mar 2026 | $55.76M | -1.8% | -2.8% | |
| LTM Mar 2026 | $50.27M | -7.3% | -2.2% | |
| LTM Mar 2026 | $41.94M | +2.1% | +2.0% | |
| LTM Jun 2026 | $0 | — | — | |
| Peer median (excluding HLS.TO) | $68.6M | +9.3% | +8.1% | |
Competitors are the stored peer set for HLS.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 60.01M | 61.47M | 63.07M | 56.62M | 56.47M |
| Cost of Revenue | 3.97M | 4.98M | 7.62M | 9M | 32.46M |
| Gross Profit | 56.04M | 56.49M | 55.45M | 47.62M | 24.01M |
| Gross Margin | 93.4% | 91.9% | 87.9% | 84.1% | 42.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 32.06M | 35.58M | 28.29M | 26.93M | 22M |
| Operating Expenses | 62.32M | 69.98M | 55.45M | 55.31M | 28.19M |
| Depreciation & Amortization | 30.26M | 34.4M | 31.94M | 22.72M | 22.2M |
| EBITDA | 25.41M | 18M | 12.88M | 17.22M | 18.02M |
| EBITDA Margin | 42.3% | 29.3% | 20.4% | 30.4% | 31.9% |
| Operating Income | (6.24M) | (13.44M) | (10.35M) | (7.69M) | (4.18M) |
| Operating Margin | -10.4% | -21.9% | -16.4% | -13.6% | -7.4% |
| Interest Income | 44K | 57K | 350K | 319K | 108.87K |
| Interest Expense | 6.96M | 7.32M | 8.75M | 10.08M | 7.22M |
| Other Income / Expenses | (5.52M) | (10.23M) | (17.45M) | (7.9M) | (8.92M) |
| Income Before Tax | (11.81M) | (23.72M) | (27.8M) | (15.58M) | (13.1M) |
| Pre-Tax Margin | -19.7% | -38.6% | -44.1% | -27.5% | -23.2% |
| Income Tax Expense | 1.31M | (124K) | (272K) | 4.07M | (452.79K) |
| Net Income | (13.12M) | (23.6M) | (27.53M) | (19.66M) | (12.65M) |
| Net Margin | -21.9% | -38.4% | -43.6% | -34.7% | -22.4% |
| EPS (Basic) | (0.41) | (0.73) | (0.85) | (0.62) | (0.40) |
| EPS (Diluted) | (0.41) | (0.73) | (0.85) | (0.62) | (0.40) |
| Weighted Avg Shares | 32.18M | 32.33M | 32.26M | 31.84M | 31.53M |
| Weighted Avg Shares (Diluted) | 32.18M | 32.43M | 32.26M | 31.84M | 31.53M |
HLS Therapeutics Inc.
TSX:HLS.TO
Intrinsic Alpha fair value
Locked
Current Price
$3.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.